KK3A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
MYQORZO Commercial AdoptionRapid growth in dispensed patients, prescriber reach, and product revenue indicates that MYQORZO is gaining early commercial traction. Continued adoption would diversify Cytokinetics beyond collaboration economics and establish a foundation for recurring product revenue as market access expands.
Late-Stage Clinical And Regulatory ProgressPositive pivotal data in non-obstructive HCM could expand aficamten’s addressable patient population beyond its current use case. The planned supplemental filing and existing MAPLE-HCM review create multiple regulatory milestones that may support broader commercialization over the next several quarters.
Strengthened LiquidityThe financing materially increases resources available for commercialization, regulatory filings, and late-stage clinical programs. A larger cash position provides greater flexibility to fund the pipeline and launch activities while reducing the immediate pressure created by the company’s substantial operating expenditures.
Bears Say
Revenue Volatility And DeclineThe sharp year-over-year decline shows that reported revenue remains highly dependent on irregular licensing and milestone payments rather than a broad, stable commercial base. Product growth may improve the mix, but near-term results can remain volatile when collaboration milestones do not recur.
Heavy Cash Burn And Persistent LossesLarge recurring cash outflows and sustained net losses require Cytokinetics to fund operations while commercialization and development programs scale. Continued burn can consume liquidity faster than product revenue builds, increasing the importance of disciplined spending and future financing capacity.
Pressured Capital StructureNegative equity combined with substantial debt indicates limited balance-sheet resilience relative to a stable issuer. This structure can constrain financial flexibility, increase reliance on capital markets, and leave less room to absorb delays in approvals, launches, or revenue growth.
Cytokinetics News
KK3A FAQ
What was Cytokinetics’s price range in the past 12 months?
Currently, no data Available
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is CHF7.21B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 06, 2026. The company reported -CHF1.236 earnings per share for the quarter, beating the consensus estimate of -CHF1.341 by CHF0.105.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.19.
How many shares outstanding does Cytokinetics have?
Currently, no data Available
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -CHF1.236 in its last earnings report, beating expectations of -CHF1.341. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CH:KK3A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF89.16 (― Upside)
CHF89.16 (― Upside)
Blogger Sentiment
Neutral
CH:KK3A Sentiment 50%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth CHF10.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.18%
12-Months-Change
Fundamentals
Return on Equity
163.98%
Trailing 12-Months
Asset Growth
57.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
KK3A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial operational and clinical progress: strong early commercial momentum for MYQORZO (rapidly growing prescriptions, rising awareness, >700 prescribers and >1,500 dispensed patients), pivotal ACACIA-HCM positive results with planned sNDA submission, successful European regulatory steps and a $760M financing that boosted cash to ~$1.7B. These strategic and scientific achievements were balanced against near-term financial headwinds including a YOY revenue decline driven by absence of milestone revenue, a wider GAAP net loss ($198.8M), sharply higher SG&A tied to launch costs and upwardly revised 2026 expense guidance. Overall, the operational wins, pivotal data and strong cash position indicate a constructive outlook for growth and future approvals, though investors should expect continued elevated spending as the company scales commercialization and pursues regulatory filings.View all CH:KK3A earnings summariesKK3A Stock 12 Month Forecast
Average Price Target
―Sarepta Therapeutics
―
PTC Therapeutics
―
Scholar Rock Holding
―
Dyne Therapeutics
―
Edgewise Therapeutics
―